Skip to main content


Figure 3 | Radiation Oncology

Figure 3

From: In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines

Figure 3

MTS proliferation assay following prolonged cilengitide treatment . Cells were treated with Cilengitide for 96 hours, followed by washing and addition of an MTS substrate. After 4 hour incubation, absorbance was read and cell viability as percent of control treated cells was reported. A) T-47D cells show the most marked response, with little to no cell growth at the 20 uM cilengitide dose. B) MCF-7 cells show a moderate growth delay. C) MDA-MB-231 cells also show a moderate growth delay. D) MDA-MB-468 cells show little to no growth delay compared to controls at this 96 hour timepoint. Most cell lines showed a dose response to cilengitide (A-C) with only MDA-MB-468 cells showing no effects. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

Back to article page